Tumor necrosis (TN) correlates with adverse outcomes in numerous solid tumors. However, its prognostic value in renal cell carcinoma (RCC) remains unclear. In this study, we performed a meta-analysis to evaluate associations between TN and cancer-specific survival (CSS), overall survival (OS), recurrence-free survival (RFS) and progression-free-survival (PFS) in RCC.
Methods
Electronic searches in PubMed, EMBASE and Web of Science were conducted according to the PRISMA statement. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were calculated to evaluate relationships between TN and RCC. A fixed- or random-effects model was used to calculate pooled HRs and 95%CIs according to heterogeneity.
Results
A total of 34 cohort studies met the eligibility criteria of this meta-analysis. The results showed that TN was significantly predictive of poorer CSS (HR = 1.37, 95% CI: 1.23–1.53, p < 0.001), OS (HR = 1.29, 95% CI: 1.20–1.40, p < 0.001), RFS (HR = 1.55, 95% CI: 1.39–1.72, p < 0.001) and PFS (HR = 1.31, 95% CI: 1.17–1.46, p < 0.001) in patients with RCC. All the findings were robust when stratified by geographical region, pathological type, staging system, number of patients, and median follow-up.
Conclusions
The present study suggests that TN is associated with CSS, OS, RFS and PFS clinical outcomes of RCC patients and may serve as a predictor of poor prognosis in these patients.
Zhenlei Zha, Wei Qu and Hu Zhao contributed equally to this work.
Abkürzungen
AJCC
American Joint Committee on Cancer
ccRCC
Clear cell renal cell carcinoma
CIs
Corresponding 95% confidence intervals
CSS
Cancer-specific survival
FE
Fixed-effects
HRs
Hazard ratios
ISUP
International Society of Urologic Pathologists
NOS
Newcastle Ottawa scale
OS
Overall survival
PFS
Progression-free-survival
PRISMA
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
RCC
Renal cell carcinoma
RE
Random-effects
RFS
Recurrence-free survival
SSIGN
Mayo Clinic Stage, Size, Grade and Necrosis
TN
Tumor necrosis
Background
Renal cell carcinoma (RCC), the third most common urologic tumor, accounts for 2–3% of all adult malignancies [1], and its incidence has continuously increased over the past few decades [2]. Although most RCC cases are diagnosed at an early stage, approximately 20% of patients undergoing curative nephrectomy will subsequently develop metastasis during the follow-up period [3]. Due to the varying efficacy of adjuvant therapies in RC, it is necessary to define more prognostic factors that will allow identification of patients at high risk of recurrence who may benefit from such treatment.
Currently, TNM stage classification [4] and the Fuhrman grade system [5] are the most important factors affecting the prognosis of patients with RCC. Additionally, several integrated prognostic models and histologic characteristics have been studied for their prognostic impact, including the American Joint Committee on Cancer (AJCC) staging system [6], International Society of Urologic Pathologists (ISUP) [7] and Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) Score [8], though these parameters are not entirely reliable. Tumor necrosis (TN) is believed to define regions of severe and chronic hypoxia, and there is renewed interest in using TN to predict prognosis after tumor resection. However, the prognostic impact of TN in RCC remains controversial, and there is increasing debate on whether TN can provide any additional information beyond grade and stage [9].
Anzeige
Hence, to further clarify the prognostic value of TN in RCC, we performed a systematic review and meta-analysis of the available published literature to evaluate whether the presence of TN has a prognostic impact on cancer-specific survival (CSS), overall survival (OS), recurrence-free survival (RFS) and progression-free-survival (PFS) in RCC patients.
Methods
Literature search strategy
According to the PRISMA guidelines [10], a comprehensive literature search was conducted using the electronic databases of PubMed, EMBASE and Web of Science up to April 2018. The MeSH terms and full text terms adopted were as follows: “kidney neoplasms”, “renal cell cancer”, “renal cell carcinoma”, “necrosis”, “tumor necrosis”, “prognosis”, “prognostic outcome”, “survival outcome”, “oncologic outcome” and their combinations. We also manually searched the reference lists of reviews, meta-analyses, and selected research articles to identify other “gray literature”. The language of the publications was restricted to English.
Inclusion and exclusion criteria
Eligible studies were selected only if they met the following criteria: (i) RCC and TN were pathologically confirmed, with all patients undergoing surgical resection; (ii) the potential prognostic value of TN for CSS, OS, RFS and PFS were reported; (iii) the authors categorically reported hazard ratios (HRs) and 95% confidence intervals (95%CIs), or they could be computed from the given data. Studies were excluded if the following criteria were met: (i) animal models or cancer cell lines were used; (ii) reviews, letters, commentaries, case reports and non-original articles; (iii) TN, clinical features and survival outcome were not analyzed; (iv) lacking sufficient data to acquire HRs and 95%CIs; (v) not in English. Additionally, when duplicate articles were found, only the most informative and recent article was adopted.
Data extraction and quality assessments
Two investigators independently extracted data of eligible studies using a standardized form for the following information: author identification, year of publication, country, period of recruitment, study design, age of patients, gender ratio, sample size, follow-up time, study design, interpretation of TN, histology and survival end point. For HRs and 95% CIs, multivariate analysis data were preferentially adopted. If these data were not available, then univariate analysis of survival outcomes was extracted instead. All discrepancies between the investigators reached a consensus through discussion. The methodological quality of the included cohort studies was assessed using the Newcastle-Ottawa scale (NOS) [11]. Each study was assessed using 8 methodology items in 3 domains with a score ranging from 0 to 9. High scores indicated high quality, a study with a score ≥ 6 was regarded as high quality, a score < 6 was regarded as low quality.
Anzeige
Statistical analysis
Statistical analyses were performed using Stata 12.0 software (Stat Corp, College Station, TX, USA). Dichotomous variables were calculated using HRs, and pooled HRs with 95% CI were used to evaluate the association of TN with RCC prognosis (CSS, OS, RFS and PFS). A heterogeneity test of the pooled HR was conducted using a Chi-square-based Q test and Higgins I2 statistic. When I2 < 50% or Pheterogeneity > 0.1, no obvious heterogeneity existed among the studies, and the fixed-effects (FE) model would be applied; otherwise, the random-effects (RE) model was applied. To obtain a more precise evaluation of heterogeneity, subgroup analysis was performed for CSS, OS and RFS based on geographical region, pathological types, staging system, No. of patients and median follow-up. Publication bias was examined using funnel plots and Egger’s linear regression test. Additionally, sensitivity analysis was used to estimate the robustness of the results via sequential omission of individual studies. A p value of < 0.05 was considered to indicate significance.
Results
Search and eligible studies
A diagram of the selection process is shown in Fig. 1. According to the search strategy, 2715 articles were retrieved from the electronic databases. By excluding 1563 duplicate reports, 1152 articles were considered potentially relevant based on screening of the titles and abstracts. The remaining articles were further excluded upon full-text review for several reasons, such as a lack of sufficient data to estimate HRs or duplicate publication in repeated cohorts. Ultimately, 34 studies [3, 12‐44] that focused on the association between RCC and TN were included for meta-analysis. The outcomes were CSS in 22 studies, OS in 17 studies, RFS in 9 studies and PFS in 5 studies.
Fig. 1
Diagram of the literature search used in this meta-analysis
×
Characteristics of the included studies
The main characteristics of the 34 eligible studies are listed in Table 1. All of the studies were published between 2005 and 2017, with a mean duration of follow-up varying from 11.7 to 102 months. The present meta-analysis was based on a total sample size of 14,084 patients, ranging from 59 to 3062 patients. The NOS was applied to assess the methodological quality of the included studies, and the results showed that all studies were of high quality (Additional file 1: Table S1). All of the included studies were based on data for retrospective analyses of survival (CSS, OS, RFS, PFS). The characteristics, including tumor features and pathologic outcomes, are summarized in Table 2. TN was detected in 31.6% (4452/14,084) of the pathological specimens from the included patients. A total of 13 of the included studies were limited to clear cell renal cell carcinoma (ccRCC), whereas 21 studies involved various tumor types, including ccRCC, papillary renal cell carcinoma, chromophobe renal cell carcinoma and unclassified tumor.
total numbers rows:36; SD standard deviation, NA data not applicable, CSS cancer-specific survival, OS overall survival, RFS recurrence-free survival, PFS progression-free survival, RD radical nephrectomy, PN partial nephrectomy
total numbers rows:36; TN+/TN tumor necrosis positive/ tumor necrosis negative, SD standard deviation, NA data not applicable, ccRCC/no-ccRCC clear cell renal cell carcinoma/non- clear cell renal cell carcinoma
Prognostic value of TN for survival outcome
The present meta-analysis demonstrated that TN in RCC is associated with poor CSS (RE HR = 1.37, 95% CI: 1.23–1.53, p < 0.001, I2 = 76.5%, Pheterogeneity < 0.001; Fig. 2a), OS (RE HR = 1.29, 95% CI: 1.20–1.40, p < 0.001, I2 = 57.6%, Pheterogeneity = 0.02; Fig. 2b), RFS (FE HR = 1.55, 95% CI: 1.39–1.72, p < 0.001, I2 = 35.6%,Pheterogeneity = 0.133; Fig. 2c) and PFS (FE HR = 1.31, 95% CI: 1.17–1.46, p < 0.001, I2 = 32.9%, Pheterogeneity = 0.202; Fig. 2d). To explore the source of heterogeneity for CSS, OS and RFS, subgroup analysis was conducted according to geographical region (Asia vs. other regions), pathological type (ccRCC vs. other types), staging system (2010 AJCC vs. other system), No. of patients (≥ 300 vs. < 300) and median follow-up (≥ 40 months vs. < 40 months). The results of this subgroup analysis again suggested that TN is a prognostic factor, despite heterogeneity among some groups (Table 3). Notably, heterogeneity for CSS, OS and RFS was significantly decreased in some models, such as geographical region in Asia, ccRCC pathological type, 2010 AJCC staging system and ≥ 300 cases.
Fig. 2
a Forest plots of studies evaluating the association between TN and CSS outcomes in RCC patients. b Forest plots of studies evaluating the association between TN and OS outcomes in RCC patients. c Forest plots of studies evaluating the association between TN and RFS outcomes in RCC patients. d Forest plots of studies evaluating the association between TN and PFS outcomes in RCC patients
Table 3
Summary and subgroup analysis for the eligible studies
Analysis specification
No. of studies
Study heterogeneity
Effects model
Pooled HR(95% CI)
p-Value
I2 (%)
Pheterogeneity
CSS
Overall
22
76.5
< 0.001
Random
1.37(1.23,1.53)
< 0.001
Geographical region
Asian
7
51.7
0.053
Random
1.34(1.12,1.59)
0.001
Other regions
15
80.8
< 0.001
Random
1.40(1.22,1.60)
< 0.001
Pathological types
ccRCC
6
0
0.775
Fixed
1.34(1.15,1.55)
< 0.001
Other types
16
81.7
< 0.001
Random
1.38(1.22,1.58)
< 0.001
Staging system
2010 AJCC
8
0
0.981
Fixed
1.30(1.17,1.44)
< 0.001
Other system
14
82.3
< 0.001
Random
1.42(1.23,1.64)
< 0.001
No. of patients
≥ 300
13
82
< 0.001
Random
1.39(1.21,1.61)
< 0.001
< 300
9
15,4
0.301
Fixed
1.33(1.16,1.51)
< 0.001
Median follow-up
≥ 40 months
12
83.3
< 0.001
Random
1.36(1.16,1.60)
< 0.001
< 40 months
9
30.2
0.177
Fixed
1.33(1.16,1.51)
< 0.001
OS
Overall
17
57.6
0.002
Random
1.29(1.20,1.40)
< 0.001
Geographical region
Asian
9
30.2
0.177
Fixed
1.38(1.25,1.51)
< 0.001
Other regions
8
58.6
0.017
Random
1.20(1.09,1.34)
< 0.001
Pathological types
ccRCC
8
48.8
0.057
Random
1.33(1.19,1.49)
< 0.001
Other types
9
62.7
0.006
Random
1.26(1.13,1.41)
< 0.001
Staging system
2010 AJCC
10
63.6
0.003
Random
1.30(1.17,1.44)
< 0.001
Other system
7
53.1
0.046
Random
1.30(1.14,1.47)
< 0.001
No. of patients
≥ 300
8
67.5
0.003
Random
1.25(1.12,1.39)
< 0.001
< 300
9
29.2
0.185
Fixed
1.35(1.22,1.49)
< 0.001
Median follow-up
≥ 40 months
13
62.6
0.001
Random
1.27(1.16,1.39)
< 0.001
< 40 months
4
0
0.412
Fixed
1.37(1.20,1.56)
< 0.001
RFS
Overall
9
35.6
0.133
Fixed
1.55(1.39,1.72)
< 0.001
Geographical region
Asian
6
42.7
0.12
Fixed
1.48(1.31,1.66)
< 0.001
Other regions
3
0
0.684
Fixed
1.87(1.41,2.37)
< 0.001
Pathological types
ccRCC
4
0
0.541
Fixed
1.61(1.40,1.86)
< 0.001
Other types
5
57.5
0.051
Random
1.46(1.25,1.71)
< 0.001
Staging system
2010 AJCC
5
54
0.069
Random
1.48(1.31,1.69)
< 0.001
Other system
4
0
0.483
Fixed
1.69(1.40,2.04)
< 0.001
No. of patients
≥ 300
4
0
0.702
Fixed
1.57(1.35,1.83)
< 0.001
< 300
5
63.4
0.027
Random
1.52(1.32,1.76)
< 0.001
Median follow-up
≥ 40 months
6
0
0.758
Fixed
1.62(1.43,1.84)
< 0.001
< 40 months
3
75.3
0.018
Random
1.39(1.16,1.68)
0.001
PFS
Overall
5
32.9
0.202
Fixed
1.31(1.17,1.46)
< 0.001
Pathological types
ccRCC
2
67.8
0.078
Random
1.44(1.20,1.71)
< 0.001
Other types
3
0
0.6
Fixed
1.23(1.07,1.41)
0.004
Staging system
2010 AJCC
2
76.3
0.04
Random
1.35(1.18,1.54)
< 0.001
Other system
3
0
0.582
Fixed
1.22(1.01,1.48)
0.036
×
Sensitivity analyses and publication bias
In sensitivity analysis excluding one study at a time, the pooled HR for CSS ranged from 1.29 (95% CI: 1.19–1.39) to 1.37 (95% CI: 1.22–1.54) (Additional file 2: Figure S1). Similarly, the pooled HR for OS ranged from 1.27 (95% CI: 1.17–1.37) to 1.31 (95% CI: 1.21–1.42) (Additional file 3: Figure S2), that for RFS from 1.52 (95% CI:1.32–1.76) to 1.66 (95% CI: 1.47–1.86) (Additional file 4: Figure S3), and that for PFS from 1.21 (95% CI:1.07–1.38) to 1.35 (95% CI: 1.12–1.63) (Additional file 5: Figure S4). These results indicate that the findings were reliable and robust. Although no statistical evidence of publication bias was observed for RFS (p-Egger = 0.135, Fig. 3c) and PFS (p-Egger = 0.932, Fig. 3d), publication bias was observed for CSS (p-Egger = 0.006, Fig. 3a) and OS (p-Egger = 0.001, Fig. 3b).
Fig. 3
a Funnel plots and Egger’s tests for the publication bias of CSS in hazard ratios (HRs). b Funnel plots and Egger’s tests for the publication bias of OS in hazard ratios (HRs). c Funnel plots and Egger’s tests for the publication bias of RFS in hazard ratios (HRs). d Funnel plots and Egger’s tests for the publication bias of PFS in hazard ratios (HRs)
×
Discussion
RCC is the most common solid lesion of the kidney, and more than 40% of patients die from this type of cancer [2]. Despite significant improvements in systemic therapy for RCC, the prognosis of patients with RCC and treatment response rates have not substantially increased [17, 42, 44]. Although several pathologic parameters, including lymphatic vessel invasion [45], tumor fat invasion [26] and primary tumor size [43], provide independent prognostic information, the likely outcome for an individual patient remains uncertain. The TNM stage and Fuhrman grade system are the most widely used approaches for RCC; however, there have been many recent suggestions for modifications based on survival trends in large case series [46]. Additionally, RCC is a highly heterogeneous disease with different clinical presentations and characteristics that remain somewhat unpredictable [47]. Therefore, it is essential to optimize the treatment and prognosis of RCC and to provide better counseling for each RCC patient.
The presence of TN in pathologic specimens may reflect the tumor biology and may also provide additional useful prognostic information. As TN results from rapid tumor proliferation and consequent outgrowth of the blood supply [41], histologic TN has been proposed to be a sign of tumor aggressiveness that generally leads to poor clinical outcomes [48]. Previous studies have investigated the association of TN with various solid tumors, including breast cancer [49], colorectal cancer [50] and lung cancer [51]. Indeed, there is renewed interest in using TN, which can be assessed in every routine pathological examination without additional costs, to more accurately predict the clinical outcome of RCC. For example, Khor et al. [20] and Ito et al. [48] reported that TN is strongly associated with poor survival and should serve as an independent prognostic factor for patients with RCC. Nonetheless, some studies have shown that the presence of any TN is a negative predictor of survival in RCC [52, 53].
To our knowledge, the present study is the first meta-analysis on the association between TN and clinical outcomes of different types of RCC. In this analysis, 14,084 RCC patients were included from 34 cohort studies, and TN was detected in 31.6% of 4452 RCC patients. Robust evidence obtained from sensitivity analysis demonstrated that the presence of TN was associated with poor outcomes in terms of CSS (HR = 1.37, p < 0.001), OS (HR = 1.29, p < 0.0 01), RFS (HR = 1.55, p < 0.001) and PFS (HR = 1.31, p < 0.001) in patients with RCC. These findings were consistently independent of geographical region, pathological type, staging system, No. of patients and median follow-up. Although there was no evidence of heterogeneity in terms of CSS or PFS, significant heterogeneity was detected in analyses of OS and RFS models. To further explore the source of heterogeneity in OS and RFS, subgroup analysis was conducted, and the data showed that significant variations were reduced in OS and RFS within some items.
Anzeige
Notably, the present study has several limitations. First, all the included studies were retrospective cohort studies, and data extracted from those studies may have led to inherent potential bias. Second, the criteria for determining the presence of TN in a pathologic specimen were inconsistent in the included studies, which may contribute to heterogeneity. Thus, rigorous morphological criteria should be used to standardize the diagnosis of TN. Third, we only included published studies written in English, and the lack of “gray literature” may cause selection bias. Fourth, substantial heterogeneity was observed in meta-analysis of CSS and OS, and although we selected the RE model according to heterogeneity, this diversity remained. Using subgroup analysis, we propose that the heterogeneity likely reflected differences in factors, such as patient and tumor characteristics. Fifth, a statistical publication bias was observed for CSS and OS according to Egger’s test. In general, studies with negative results tend not to be submitted or published; therefore, a certain degree of publication bias was observed in the present study. Finally, it should be noted that factors, including age, sex, histology type and surgical method, that may affect survival outcomes were adequately controlled.
Nevertheless, the present study has several key strengths. First, the meta-analysis included 34 studies with large sample sizes, with the ability to detect more stable associations between TN and clinical outcomes of RCC patients. Second, with strict inclusion and exclusion criteria, we extracted available data from relevant studies. Furthermore, through subgroup and sensitivity analyses, the results were reliable and robust. Therefore, TN determination, with excellent accessibility and low costs, warrants wider application in patients with RCC for risk stratification and decision-making of individualized treatment.
Conclusions
In conclusion, the results of the present meta-analysis demonstrate that TN in histopathology is associated with poor CSS, OS, RFS and PFS in patients with RCC. Due to the limitations of the present study, large-scale, multicenter prospective studies with long-term follow-up are needed to verify these results.
Availability of data and materials
All data generated or analyzed during the present study are included in this published article (and its additional files).
Anzeige
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Anzeige
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
